File size: 71,416 Bytes
b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c 8e441ee b74754c 8e441ee b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 8e441ee bd6ab73 b74754c bd6ab73 8e441ee bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c bd6ab73 b74754c | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 | ---
tags:
- sentence-transformers
- sentence-similarity
- feature-extraction
- dense
- generated_from_trainer
- dataset_size:2369
- loss:MultipleNegativesRankingLoss
- dataset_size:6288
base_model: AI-Growth-Lab/PatentSBERTa
widget:
- source_sentence: "COMPOSITIONS COMPRISING OR CONSISTING OF POLYDATIN FOR USE IN\
\ TREATMENT OF BONE DISEAS. Title: COMPOSITIONS COMPRISING OR CONSISTING OF POLYDATIN\
\ FOR USE IN TREATMENT OF BONE DISEAS\n\nAbstract: \n\nBusiness Description: The\
\ patent concerns the possible use of polydatin for the treatment of pathologies\
\ characterized by reduced bone mass. Polydatin is an oligostilbene that can be\
\ extracted in abundant quantities from the roots of the Polygonum Cuspidatum\
\ plant and, according to our studies about osteoblastic proliferation and differentiation,\
\ is able to increase osteogenic activity.\n\nTech Features: Skeletal pathologies\
\ are widespread in the world population, more than 200 million people are osteoporosis\
\ patients and have a high probability of fracture. Polydatin is a substance of\
\ natural origin, free of the side effects related to the use of synthetic drugs, currently\
\ administered for the treatment of bone loss diseases . Our experiments carried\
\ out in two-dimensional cultures (2D) and in cells grown on Scaffold (3D), have\
\ shown that polydatin is able to increase the activity of osteoblasts (ALP) and\
\ the deposition of Bone Matrix. The compositions comprising or consisting of\
\ polydatin may be administered orally (for example capsules or tablets, solutions,\
\ emulsions) or topically (oils, creams, ointments), or even through an appropriate\
\ enrichment of the active ingredient in functional foods\n\nApplications: Patients\
\ with traumatic-degenerative pathologies of the skeleton and oral cavity; Osteoporosis\
\ patients;\n\nAdvantages: Molecule of natural origin; Antioxidant activity on\
\ the whole organism; Possibility of topical use;"
sentences:
- "Inhibitory compounds neurodegeneration and tumors. Title: Inhibitory compounds\
\ neurodegeneration and tumors\n\nAbstract: \n\nBusiness Description: The inhibition\
\ of the monoacylglycerol lipase enzyme (MAGL), naturally present in many brain\
\ cells and involved in physio-pathological processes, has a high therapeutic\
\ potential: neurodegenerative inflammation pathologies and tumors could be treated\
\ with new reversible inhibitory compounds, which would reduce the side effects\
\ of the irreversible inhibitors tested so far.\n\nTech Features: Monoacylglycerol\
\ lipase (MAGL) is a human enzyme of the endocannabinoid system involved in numerous\
\ physio-pathological processes (regulation of inflammation, anxiety, immune modulation,\
\ motor coordination ...), yet its overexpression/upregulation can cause neuroinflammatory\
\ diseases and tumors. The inhibition of MAGL for therapeutic purposes has been\
\ studied so far with irreversible inhibitors, which however nullify the enzyme\
\ activity, leading to a progressive loss of the therapeutic effect and to addiction\
\ phenomena. On the contrary, the new-patented compounds based on a strong non-covalent\
\ reversible mechanism of action avoid the side effects mentioned. Effective in\
\ laboratory on various tumor cell lines (e.g. colorectal, breast and ovarian\
\ cancer), they could also treat other MAGL-mediated pathologies (neuroinflammation/degeneration,\
\ pain, amyotrophic multiple/lateral sclerosis, Alzheimer's disease, Parkinson's\
\ disease). Link to scientific publication and information on Ca' Foscari website\n\
\nApplications: Innovative and less harmful pharmaceutical compositions for the\
\ treatment of serious neurodegenerative pathological conditions; Innovative and\
\ less harmful pharmaceutical compositions for cancer treatment.\n\nAdvantages:\
\ Temporary nature and reversibility; Drastic reduction of side effects; High\
\ efficacy tested on tumor cell lines; Exploitable to treat numerous neurodegenerative\
\ diseases; One of the few non-covalent reversible MAGL inhibitors with high efficacy."
- 'New computational method for the prognosis of amyotrophic lateral sclerosis.
Title: New computational method for the prognosis of amyotrophic lateral sclerosis
Abstract: A method is described for determining a disease progression and survival
prognosis, at a succession of prediction times, for patients suffering from amyotrophic
lateral sclerosis (ALS). The method comprises a step of defining a set of variables
associated with the onset and progression of amyotrophic lateral sclerosis, comprising
a first group of variables associated with the onset of amyotrophic lateral sclerosis
(comprising at least the variables “patient sex”, “disease onset age”, “disease
onset site”), a second group of dynamic time variables (comprising at least the
variable “time elapsed since disease onset”), a third group of dynamic functional
variables (comprising at least one of the variables breathing, swallowing, communicating,
walking/self-care or at least one variable of a functional progression and/or
severity scale of amyotrophic lateral sclerosis), and further at least one variable
associated with survival. The method further provides for encoding by means of
a Dynamic Bayesian Network, using at least one trained algorithm, a plurality
of probabilistic conditional dependence relationships, in which each relationship
is a probabilistic conditional dependence relationship between two of the aforesaid
variables. The aforesaid prediction times are defined so that each prediction
time belongs to a respective time interval in which the conditional dependence
relationships between the variables are stationary. The method further involves
describing the Dynamic Bayesian Network, using at least one trained algorithm,
by means of a corresponding graph, comprising said variables as nodes and comprising
topological connections oriented between nodes corresponding to variables among
which a probabilistic conditional dependence is identified. In the graph, given
a node, the connections entering it show a conditional probability of the value
assumed by the variable associated with such node, in a given prediction time,
depending on the values assumed, in a prior prediction time, from the variables
associated with the nodes from which such connections originate. The method further
comprises the steps of entering, for each of the defined variables, data acquired
at a given acquisition time relating to the situation of a specific patient; and
calculating, by electronic processing and/or calculating means, on the basis of
the Dynamic Bayesian Network and the graph, and starting from the aforesaid acquired
data, the values of each of the defined variables, at one or more prediction times
following the acquisition time. Finally, the method involves obtaining, in a given
prediction time, disease progression prognosis results on the basis of the values
of one or more of the variables of the third group calculated in such prediction
time; and the survival prognosis results on the basis of the value of at least
one variable associated with survival, calculated at such prediction time.
Business Description: The invention relates to a new probabilistic model based
on dynamic Bayesian networks: by introducing specific clinical data of patients
suffering from amyotrophic lateral sclerosis (ALS), the model object of the invention
allows to predict the course of the disease, the loss of autonomy in specific
functional domains and the survival, and to identify risk factors of the disease.
Tech Features: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease,
characterized by progressive muscle paralysis caused by motor neuron degeneration.
The onset and progression of ALS are very heterogeneous, making the development
of personalised approaches extremely difficult. The invention consists of a probabilistic
predictor of ALS progression, based on a dynamic Bayesian network built using
a database of over 4000 patients treated at specialised centres in Italy and Israel.
By intoducing the clinical information of a new ALS subject, the invention allows
to simulate the clinical course and to probabilistically predict the risk of impairment
of the functional domains typical of ALS and the survival, representing an important
tool to support clinical decision-making and the drafting of the treatment plan.
Applications: Online platform (SaaS)/software for predicting ALS progression;
Support to clinical decision and drafting of the treatment plan; Institutional
stakeholder decision support; In silico generation of patient populations with
specific characteristics.
Advantages: Prediction of ALS progression; Personalized medicine approach; Clinical
decision support; Identification of new prognostic markers; Possible alternative
to placebo cohorts in clinical trials.'
- "COMPOSITIONS COMPRISING OR CONSISTING OF POLYDATIN FOR USE IN TREATMENT OF BONE\
\ DISEAS. Title: COMPOSITIONS COMPRISING OR CONSISTING OF POLYDATIN FOR USE IN\
\ TREATMENT OF BONE DISEAS\n\nAbstract: \n\nBusiness Description: The patent concerns\
\ the possible use of polydatin for the treatment of pathologies characterized\
\ by reduced bone mass. Polydatin is an oligostilbene that can be extracted in\
\ abundant quantities from the roots of the Polygonum Cuspidatum plant and, according\
\ to our studies about osteoblastic proliferation and differentiation, is able\
\ to increase osteogenic activity.\n\nTech Features: Skeletal pathologies are\
\ widespread in the world population, more than 200 million people are osteoporosis\
\ patients and have a high probability of fracture. Polydatin is a substance of\
\ natural origin, free of the side effects related to the use of synthetic drugs, currently\
\ administered for the treatment of bone loss diseases . Our experiments carried\
\ out in two-dimensional cultures (2D) and in cells grown on Scaffold (3D), have\
\ shown that polydatin is able to increase the activity of osteoblasts (ALP) and\
\ the deposition of Bone Matrix. The compositions comprising or consisting of\
\ polydatin may be administered orally (for example capsules or tablets, solutions,\
\ emulsions) or topically (oils, creams, ointments), or even through an appropriate\
\ enrichment of the active ingredient in functional foods\n\nApplications: Patients\
\ with traumatic-degenerative pathologies of the skeleton and oral cavity; Osteoporosis\
\ patients;\n\nAdvantages: Molecule of natural origin; Antioxidant activity on\
\ the whole organism; Possibility of topical use;"
- source_sentence: "OFFLOADNN. Title: OFFLOADNN\n\nAbstract: \n\nBusiness Description:\
\ Resource availability at the edge is generally limited, with particular regard\
\ to memory consumption of DNNs, rarely considered as a limiting factor to the\
\ execution of tasks at the edge. Furthermore, the structure of the DNNs required\
\ for different CV inference tasks and the correlation among them have often been\
\ overlooked. Accounting for all this, the invention decreases the resource consumption\
\ of DNNs dedicated to run CV tasks, which in turn allow to run more tasks or\
\ to decrease the energy consumption with the same number of running tasks.\n\n\
Tech Features: The invention is OffloaDNN, a framework to support the scalable\
\ offloading of computer vision (CV) tasks to the edge. We formulated the problem\
\ of DNN for scalable Offloading of Tasks (DOT) to find the optimal configuration\
\ of the DNN, the tasks that can be admitted and the allocation of compute and\
\ network resources to assign to the tasks. DOT minimizes the task rejection rate\
\ and resource consumption, while meeting the accuracy and latency requirements\
\ of admitted tasks. As the DOT is NP-hard, and therefore complex to solve to\
\ optimality, OffloaDNN solves the DOT efficiently using a weighted tree-based\
\ graph modeling of the feasible solutions. The invention allows to decrease the\
\ resources needed at the edge, also allowing for multiple task execution when\
\ these require the same DNN components. The lowering of resources needed implies\
\ also a lower energy consumption with operational savings.\n\nApplications: Computer\
\ vision tasks using edge computing.\n\nAdvantages: Lower resources needed at\
\ the edge; Lower energy consumption; Lower operative costs."
sentences:
- "OFFLOADNN. Title: OFFLOADNN\n\nAbstract: \n\nBusiness Description: Resource availability\
\ at the edge is generally limited, with particular regard to memory consumption\
\ of DNNs, rarely considered as a limiting factor to the execution of tasks at\
\ the edge. Furthermore, the structure of the DNNs required for different CV inference\
\ tasks and the correlation among them have often been overlooked. Accounting\
\ for all this, the invention decreases the resource consumption of DNNs dedicated\
\ to run CV tasks, which in turn allow to run more tasks or to decrease the energy\
\ consumption with the same number of running tasks.\n\nTech Features: The invention\
\ is OffloaDNN, a framework to support the scalable offloading of computer vision\
\ (CV) tasks to the edge. We formulated the problem of DNN for scalable Offloading\
\ of Tasks (DOT) to find the optimal configuration of the DNN, the tasks that\
\ can be admitted and the allocation of compute and network resources to assign\
\ to the tasks. DOT minimizes the task rejection rate and resource consumption,\
\ while meeting the accuracy and latency requirements of admitted tasks. As the\
\ DOT is NP-hard, and therefore complex to solve to optimality, OffloaDNN solves\
\ the DOT efficiently using a weighted tree-based graph modeling of the feasible\
\ solutions. The invention allows to decrease the resources needed at the edge,\
\ also allowing for multiple task execution when these require the same DNN components.\
\ The lowering of resources needed implies also a lower energy consumption with\
\ operational savings.\n\nApplications: Computer vision tasks using edge computing.\n\
\nAdvantages: Lower resources needed at the edge; Lower energy consumption; Lower\
\ operative costs."
- 'Polymeric endodontic instruments. Title: Polymeric endodontic instruments
Abstract: The present invention relates to an endodontic tool for shaping a dental
root canal, wherein said tool comprises a handle (13), a tang (11), and a stem
(10) made of polymeric material and comprising a tip (12) and at least one helically
developing cutting edge (100), and wherein said stem (10) develops along a longitudinal
axis (A-A). The stem (10) has a substantially conical or tapering twisted shape,
in particular said stem (10) having a solid cross-section with a diameter increasing
from the tip (12) to the tang (11).
Business Description: Endodontic files for shaping canal roots are made of Ni-Ti
alloy or stainless steel. Production, based on precision micromechanics processes,
involves high costs and time. Production limitations affect the geometries, especially
near the tip, reducing cutting efficiency. Another critical issue is the potential
failure of the instrument during treatment, which can trap it in the canal and
require invasive procedures for the patient.
Tech Features: The analysis of materials databases has identified families of
biocompatible polymers, potentially reinforced, capable of sustaining the applied
loads even better than the traditional metallic materials used for endodontic
files. The selected polymers offer advantages in terms of fatigue resistance and
reduced costs. However, they present critical issues related to hardness and torsion
resistance, which are fundamental characteristics for the shaping of the canal
root. To address these issues, the use of biocompatible surface coatings with
high hardness and low friction coefficient is proposed, applicable through technologies
such as chemical vapor deposition. These coatings can significantly improve the
surface resistance of polymers, making them suitable for use in endodontic files.
Applications: Biocompatible polymers have been identified that withstand critical
stresses leading to the failure of metallic tools during canal shaping; The identified
polymers, with lower density and cost compared to metals, allow the use of inexpensive
mass production technologies.
Advantages: Drastic reduction in production costs; Reduction or elimination of
the risk of instrument failure in the canal; Creation of innovative geometries
through 3D printing or injection molding for large-scale production.'
- 'Unidirectional mechanical device. Title: Unidirectional mechanical device
Abstract: Unidirectional mechanical device comprising at least one array (10;
20) of three or more cells (100; 200). Each cell (100; 200) of the array comprises:
a floating mass (101; 201); at least one first elastic element (102; 202) connecting
the floating mass (101; 201) to a reference external structure for the unidirectional
mechanical device, wherein the at least one first elastic element (102; 202) comprises
at least one first folded beam; at least one second elastic element (103) connecting
the floating mass (101) to a second floating mass of a preceding cell of the at
least one array (10), wherein the at least one second elastic element (103) comprises
at least one second folded beam; at least one third elastic element (104) connecting
the floating mass (101) to a third floating mass of a succeeding cell of the at
least one array (10), wherein the at least one third elastic element (104) comprises
at least one third folded beam; an electric system configured to control a potential
difference acting on the floating mass (101; 201), determining an overall electrostatic
stiffness of the at least one array (10; 20).
Business Description: The invention consists of a mono-directional mechanical
filter at a micrometric scale, which can be integrated into MEMS systems. In certain
frequency bands, the device allows the propagation of mechanical waves in only
one direction, blocking those travelling in the opposite direction. We obtain
this filter by means of a periodic structure with time-modulated stiffness, here
achieved by regulating suitable voltages.
Tech Features: In mechanics, the principle of reciprocity dictates that a system
excited at point A and observed at point B behaves in the same way if excited
at B and observed at A. One of the ways to create a non-reciprocal system is to
break temporal invariance. A substantial number of scientific works in recent
years have dealt with the theoretical and experimental description of these systems,
created through periodic structures of time-varying stiffness. However, these
works remain confined to the level of speculation and demonstrative prototypes
to the macro-scale, with complicated and difficult to implement solutions. The
present invention realizes the above principles in an easy-to-produce MEMS device
by using an electrostatic principle for the modulation of the stiffness which,
since it is not present at the macro-scale but only at the micro-scale, had not
been considered with this aim up to now. Essentially, the system is made up of
the repetition of some elementary cells, made up of springs and masses that house
an electrode with parallel faces for modulation. We speculate that this new type
of system can be used both as a new sensor and/or as a component (e.g. filter)
in more complex systems.
Applications: MEMS directional sensor; Directional filter for devices that use
elastic waves as the main means of transduction.
Advantages: Uses mechanical waves; Mechanical device with non-symmetrical response
(equivalent of an electric diode); Lower frequencies as compared to electromagnetic
waves; Can be manufactured using traditional MEMS technologies.'
- source_sentence: "GEL FORMULATION FOR THE ORAL ADMINISTRATION OF DRUGS IN PARTICULAR\
\ TO DYSPHAGIC PATIENTS. Title: GEL FORMULATION FOR THE ORAL ADMINISTRATION OF\
\ DRUGS IN PARTICULAR TO DYSPHAGIC PATIENTS\n\nAbstract: \n\nBusiness Description:\
\ The present invention relates to a gel formulation containing water-soluble\
\ active ingredients mainly available on the pharmaceutical market as oral solid\
\ dosage forms such as immediate-release tablets or capsules or powders or granules\
\ for oral use. The formulation object of the present invention satisfies the\
\ particular needs of patients who show anomalies in the swallowing process. The\
\ pathological condition related to swallowing problems is called dysphagia.\n\
\nTech Features: The present invention provides a method for reformulating water-soluble\
\ drugs, when commercially available for oral administration only in solid form\
\ with immediate release, mostly tablets and / or capsules without neglecting\
\ the existence of granules and powders for oral use. Drugs are reformulated as\
\ semi-solid preparations suitable for oral administration in patients with swallowing.\
\ This method allows to obtain an unchanged release of the active ingredient,\
\ compared to that of the drug formulated in the original dosage form. The present\
\ patent therefore describes a semi-solid formulation with rheological characteristics\
\ comparable to commercially gelled drinks, used for hydration and the administration\
\ of therapy to patients with swallowing disorders.\n\nApplications: Avoid any\
\ handling operations by eliminating the dangers associated with loss of active\
\ substance; Avoid contamination and dosage errors with greater safety in the\
\ administration of drugs; The active substance is formulated in a dosage form\
\ with a consistency suitable for swallowing in the dysphagic patients without\
\ its release kinetics being altered.\n\nAdvantages: Potential applicability in\
\ hospital pharmacies to standardize, optimize and automate the galenic preparations\
\ of drugs available only as tablets; Large-scale marketing can improve the therapeutic\
\ possibilities for dysphagia patients; Industrial production may cover a market\
\ share, which is currently entrusted to galenic production in a pharmacy."
sentences:
- "Supplement for psychiatric disorders. Title: Supplement for psychiatric disorders\n\
\nAbstract: \n\nBusiness Description: The present invention relates to an ester\
\ of a phospholipid with conjugated linoleic acid (CLA) as a nutritional supplement\
\ in treatment of psychiatric disorders with neuroinflammatory and neurodegenerative\
\ basis, such as depression, bipolar disorder and schizophrenia.\n\nTech Features:\
\ The search for alternative therapies in place of non-steroidal anti-inflammatory\
\ drugs for neuroinflammation is crucial since the risk of side effects derived\
\ from their use has been demonstrated especially during pregnancy with serious\
\ outcomes such as the development of sexual organs in the fetus as well as subsequent\
\ psychiatric trajectory in the offspring life in both sexes. Therefore, an alternative\
\ therapeutic approach would be resolutive to pharmacological treatment. We have\
\ shown in in-vivo models that the dietary intake of 0.5% CLA (i) increases omega-3\
\ DHA fatty acid levels by approx. 10 times in both the maternal and fetal liver,\
\ and approx. 5 times in the fetal brain; (ii) increases gene expression of PPAR\
\ alpha and its PEA and OEA ligands. These molecules are known to exert a potent\
\ anti-neuroinflammatory activity and thereby a protective effect against those\
\ psychiatric disorders with neuroinflammatory basis. Furthermore, as ester of\
\ a phospholipid the bioavailability of CLA is increased.\nTRL= 3 - 4 ( in-vivo\
\ )\n\nApplications: Psychiatric disorders with neuroinflammatory basis such as\
\ depression, bipolar disorder and schizophrenia.\n\nAdvantages: Absence of side\
\ effects; Suitable also during critical windows of vulnerability such as pregnancy\
\ and infancy; CLA can be formulated as a functional food, facilitating its compliance."
- "Safepack: Safety Backpack for riders. Title: Safepack: Safety Backpack for riders\n\
\nAbstract: \n\nBusiness Description: Safepack is the first smart backpack designed\
\ for Gig Economy delivery service riders. It is fully integrated into the work\
\ dynamics and improves user safety by reducing the possibility of distraction\
\ and enhancing communication with other road users.\n\nTech Features: Safepack\
\ consists of: 1) Tactile navigation system, inserted in the belt, consisting\
\ of piezoelectric actuators that vibrate in the direction of the path to follow\
\ and an inflation system that ensures the fitting and correct perception of the\
\ vibration. 2) Communication system based on voice interface (Speaker and microphone):\
\ the rider can receive information from the platform, such as the delivery of\
\ a new order (collection / delivery point, distance, compensation), can accept\
\ or reject it and communicate delays or emergencies. 3) Automatic lighting system,\
\ aimed at improving communication with other road users. The light is generated\
\ by side-emitting optical fibers connected to a yellow LED for the visibility\
\ lights, and red LEDs for the directional and brake lights. Finally, Safepack\
\ communicates via bluetooth with the platform app and with the navigation app.\
\ The volume of the voice interface and the intensity of the vibration can be\
\ adjusted thanks to a pressure sensor placed in the right shoulder strap.\n\n\
Applications: Riders working in Gig economy delivery services.\n\nAdvantages:\
\ A smart product perfectly integrated into the working dynamics of the delivery\
\ platforms; Offers a support tool that allows a rider not to have to constantly\
\ look at a smartphone to receive navigation instructions and information from\
\ the platform app; Improves rider safety by reducing distracting factors, making\
\ him visible and communicating his movements to other road users."
- "GEL FORMULATION FOR THE ORAL ADMINISTRATION OF DRUGS IN PARTICULAR TO DYSPHAGIC\
\ PATIENTS. Title: GEL FORMULATION FOR THE ORAL ADMINISTRATION OF DRUGS IN PARTICULAR\
\ TO DYSPHAGIC PATIENTS\n\nAbstract: \n\nBusiness Description: The present invention\
\ relates to a gel formulation containing water-soluble active ingredients mainly\
\ available on the pharmaceutical market as oral solid dosage forms such as immediate-release\
\ tablets or capsules or powders or granules for oral use. The formulation object\
\ of the present invention satisfies the particular needs of patients who show\
\ anomalies in the swallowing process. The pathological condition related to swallowing\
\ problems is called dysphagia.\n\nTech Features: The present invention provides\
\ a method for reformulating water-soluble drugs, when commercially available\
\ for oral administration only in solid form with immediate release, mostly tablets\
\ and / or capsules without neglecting the existence of granules and powders for\
\ oral use. Drugs are reformulated as semi-solid preparations suitable for oral\
\ administration in patients with swallowing. This method allows to obtain an\
\ unchanged release of the active ingredient, compared to that of the drug formulated\
\ in the original dosage form. The present patent therefore describes a semi-solid\
\ formulation with rheological characteristics comparable to commercially gelled\
\ drinks, used for hydration and the administration of therapy to patients with\
\ swallowing disorders.\n\nApplications: Avoid any handling operations by eliminating\
\ the dangers associated with loss of active substance; Avoid contamination and\
\ dosage errors with greater safety in the administration of drugs; The active\
\ substance is formulated in a dosage form with a consistency suitable for swallowing\
\ in the dysphagic patients without its release kinetics being altered.\n\nAdvantages:\
\ Potential applicability in hospital pharmacies to standardize, optimize and\
\ automate the galenic preparations of drugs available only as tablets; Large-scale\
\ marketing can improve the therapeutic possibilities for dysphagia patients;\
\ Industrial production may cover a market share, which is currently entrusted\
\ to galenic production in a pharmacy."
- source_sentence: 'TARGETING SMALL RNAS AS A THERAPY FOR ALS. Title: TARGETING SMALL
RNAS AS A THERAPY FOR ALS
Abstract: The present invention relates to an inhibitor of miR-129, relative compounds
and pharmaceutical compositions for use in the treatment and/or prevention of
amyotrophic lateral sclerosis and Alzheimer''s disease. The invention also relates
to a method for the diagnosis and/or prognosis of Alzheimer''s disease in a subject
or to identify a subject at risk to develop amyotrophic lateral sclerosis or Alzheimer''s
disease and to a method for the measuring the efficacy of a therapy for amyotrophic
lateral sclerosis or for Alzheimer''s disease and relative kits.
Business Description: We propose to develop a drug product to treat all forms
of ALS by targeting an important pathogenic pathway, miR-129-1 that is up-regulated
in both familial and sporadic ALS patients, in human and SOD1 G93A mice (A-B).
Antisense technology is entering a phase of clinical successes and we believe
that our strategy can provide clinically meaningful benefit to patients that have
no therapeutic hope. To date, current approved treatments for ALS, which at best
guarantee a span life extension of 3 months, are riluzole (Li et al., Plos One
2013) and edaravone (Ito et al, Exp Neurol, 2008) .
Tech Features: Our proposed miR-129-1 PMO therapeutic strategy outperformed when
compared with these ALS approved molecules. Our patented a miR-129-1 modulation
strategy with a Morpholino Antisense Oligonucleotide (ASO-PMO) and demonstrated
in vivo that it recovers the expression of its target protein HuD, allowing for
a 12.5% increase in survival and an improvement neuromuscular performance of
SOD1 G93A mice, a genetic model of ALS, treated in the pre-symptomatic phase. To
improve miR-129-1 PMO therapeutic efficacy, better delivery to target tissue is
needed: based on our experimental data from another study on motor neuron disease,
an arginine-rich peptide conjugated with PMO (CPP-PMO) shows an increased efficacy
in vivo . In addition, the mouse model TDP43 can be used to demonstrate a more
general efficacy of the product, before proceeding with toxicological and pharmacokinetic
evaluation in the preclinical setting. In addition, the mouse model TDP43 can
be used to demonstrate a more general efficacy of the product, before proceeding
with toxicological and pharmacokinetic evaluation in the preclinical setting.
Applications: Familial amyotrophic lateral sclerosis, Sporadic amyotrophic lateral
sclerosis, Alzheimer Disease, Epilepsy, Fragile X syndrome, Tubero sclerosis complex
and Cornea pathologies.
Advantages: Targeting miRNA allows modulation of a large number of target genes;
PMO works as a steric-blocker, a more effective strategy when the target is a
miRNA; PMO is superior to small molecules for improved target affinity; PMO fulfills
important criteria of solubility, stability, binding affinity, in vitro and in
vivo efficacy and in vivo toxicity if compared to other chemistries; PMO has low
risk in terms of toxicity, off target effects and immune response stimulation.'
sentences:
- 'Antimicrobial dental adhesive graphene-based. Title: Antimicrobial dental adhesive
graphene-based
Abstract: Disclosed is a dental adhesive including a polymeric adhesive and a
nanofiller dispersed in the polymeric adhesive, the nanofiller being constituted
by graphene nanostructures which are properly dispersed inside the polymer adhesive
and over the surface of the adhesive layer without formation of agglomerates,
so that the dental adhesive exhibits significant antimicrobial and antibiofilm
properties against pathogens of the oral cavity.
Business Description: The patent is based on a dental adhesive with antimicrobial
and anti-biofilm properties taking advantage of the use of graphene-based micro
and nanometer fillers. The nanomaterials introduced into an adhesive are uniformly
dispersed, without agglomerations inside the polymer and partially exposed over
the adhesive surface. These significantly inhibit, by mechanical action, adhesion
and bacterial growth.
Tech Features: The adhesive object of the patent consists of a dental adhesive
composed of BisGMA, filled with graphene-based nanoplachets (GNP), produced at
low cost by thermal expansion, or its derivatives incorporated in the polymer
matrix. Adhesives have strong antimicrobial properties against the bacteria that
typically populate the oral cavity, such as Streptococcus mutants. Current commercial
adhesives use nanometric fillers, in particular barium glass, zirconium oxide,
aluminum oxide, or silicon dioxide, for the sole purpose of increasing the micromechanical
adhesion between the adhesive and dentin or enamel, and therefore typically do
not have specific properties. antimicrobials. The antimicrobial dental adhesives
used have limitations, as organic fillers tend to worsen the mechanical characteristics
of dental materials. In fact, these fillers are subject to shrinkage after the
cure and polymerization phase, just like the matrix and therefore limit the mechanical
strength of the composite.
Applications: Dental adhesive with antimicrobial properties.
Advantages: The particular production process of the new adhesive possess antimicrobial
properties; The production of this adhesive does not require structural changes
to companies producing dental adhesives; GNP possess the properties of the basal
plane typical of 2D graphene, at a lower cost and without its technological problems.
Moreover they can be used on a large scale.'
- "OXYSTEROL FOR THE TREATMENT AND PREVENTION OF CORONAVIRUS DISEASES. Title: OXYSTEROL\
\ FOR THE TREATMENT AND PREVENTION OF CORONAVIRUS DISEASES\n\nAbstract: \n\nBusiness\
\ Description: The invention aims to provide antiviral compounds for the prevention\
\ and treatment of infections caused by a coronavirus, particularly by SARS-CoV-2.\
\ The invention shows that 27-hydroxycholesterol can activate the innate immune\
\ response and induce the response of cells and tissues. Formulated in a pharmaceutical\
\ composition, it significantly inhibits the infectivity of SARS-CoV-2 (100% at\
\ the highest doses).\n\nTech Features: An oxysterol called 27-hydroxycholesterol\
\ (27OHC), a derivative of cholesterol obtained by oxidation, endogenous, that\
\ is, produced naturally by the human body, has been identified as an antiviral\
\ compound. In fact, in vitro tests, 27OHC was administered after inoculating\
\ susceptible cells with SARS-CoV-2, simulating a viral infection treatment protocol.\
\ 27OHC was able to inhibit the replication of SARS-CoV-2 and other human coronavirus\
\ that causes the common cold (HCoV-OC43), without cytotoxicity, at concentrations\
\ in the micromolar range.\n\nThis study has been published on the journal Redox\
\ Biology and is available ( https://doi.org/10.1016/j.redox.2020.101682 ).\n\n\
Applications: Pharmaceutical sector; Respiratory diseases; Chronic inflammatory\
\ gastrointestinal diseases.\n\nAdvantages: New treatment for SARS-CoV-2; Treatment\
\ active against other Coronaviruses; Physiological drug naturally present in\
\ the human organism."
- 'TARGETING SMALL RNAS AS A THERAPY FOR ALS. Title: TARGETING SMALL RNAS AS A THERAPY
FOR ALS
Abstract: The present invention relates to an inhibitor of miR-129, relative compounds
and pharmaceutical compositions for use in the treatment and/or prevention of
amyotrophic lateral sclerosis and Alzheimer''s disease. The invention also relates
to a method for the diagnosis and/or prognosis of Alzheimer''s disease in a subject
or to identify a subject at risk to develop amyotrophic lateral sclerosis or Alzheimer''s
disease and to a method for the measuring the efficacy of a therapy for amyotrophic
lateral sclerosis or for Alzheimer''s disease and relative kits.
Business Description: We propose to develop a drug product to treat all forms
of ALS by targeting an important pathogenic pathway, miR-129-1 that is up-regulated
in both familial and sporadic ALS patients, in human and SOD1 G93A mice (A-B).
Antisense technology is entering a phase of clinical successes and we believe
that our strategy can provide clinically meaningful benefit to patients that have
no therapeutic hope. To date, current approved treatments for ALS, which at best
guarantee a span life extension of 3 months, are riluzole (Li et al., Plos One
2013) and edaravone (Ito et al, Exp Neurol, 2008) .
Tech Features: Our proposed miR-129-1 PMO therapeutic strategy outperformed when
compared with these ALS approved molecules. Our patented a miR-129-1 modulation
strategy with a Morpholino Antisense Oligonucleotide (ASO-PMO) and demonstrated
in vivo that it recovers the expression of its target protein HuD, allowing for
a 12.5% increase in survival and an improvement neuromuscular performance of
SOD1 G93A mice, a genetic model of ALS, treated in the pre-symptomatic phase. To
improve miR-129-1 PMO therapeutic efficacy, better delivery to target tissue is
needed: based on our experimental data from another study on motor neuron disease,
an arginine-rich peptide conjugated with PMO (CPP-PMO) shows an increased efficacy
in vivo . In addition, the mouse model TDP43 can be used to demonstrate a more
general efficacy of the product, before proceeding with toxicological and pharmacokinetic
evaluation in the preclinical setting. In addition, the mouse model TDP43 can
be used to demonstrate a more general efficacy of the product, before proceeding
with toxicological and pharmacokinetic evaluation in the preclinical setting.
Applications: Familial amyotrophic lateral sclerosis, Sporadic amyotrophic lateral
sclerosis, Alzheimer Disease, Epilepsy, Fragile X syndrome, Tubero sclerosis complex
and Cornea pathologies.
Advantages: Targeting miRNA allows modulation of a large number of target genes;
PMO works as a steric-blocker, a more effective strategy when the target is a
miRNA; PMO is superior to small molecules for improved target affinity; PMO fulfills
important criteria of solubility, stability, binding affinity, in vitro and in
vivo efficacy and in vivo toxicity if compared to other chemistries; PMO has low
risk in terms of toxicity, off target effects and immune response stimulation.'
- source_sentence: "High reduction and backdrivability ACTUATion SYSTEM with minimal\
\ lateral encumbrance. Title: High reduction and backdrivability ACTUATion SYSTEM\
\ with minimal lateral encumbrance\n\nAbstract: \n\nBusiness Description: Typical\
\ robotic actuation units have a motor and its transmission system aligned with\
\ the axis of the joint they actuate, resulting in large lateral encumbrance of\
\ the whole system.\n\nThis solution aims at solving this problem and allows to\
\ locate the last transmission stage at an arbitrary distance from the axis of\
\ the screw.\n\nTech Features: This invention consists in a class of actuation\
\ systems which is specifically designed to minimize the lateral encumbrance of\
\ the exoskeletal system to maximize its practical usability. Its core components\
\ are a motor coupled to a leadscrew or ballscrew system and a further (arbitrary)\
\ transmission system to connect the nut of the screw based transmission to the\
\ output wheel.\n\nFurthermore, this solution allows to displace the location\
\ of the screw with respect to the final transmission stage, allowing the adaptation\
\ of the location of the different stages of the system without influencing the\
\ overall behavior.The designed anti-blockage system guarantees proper functioning\
\ of each mechanical component and high back-drivability of the overall system\
\ even for high overall gearing.\n\nApplications: Robotics.\n\nAdvantages: Minimal\
\ lateral encumbrance; High gearing; Highly Back-drivable; Torque estimation through\
\ current measurement; Capability of dislocating the screw from the point of application\
\ of force."
sentences:
- "High reduction and backdrivability ACTUATion SYSTEM with minimal lateral encumbrance.\
\ Title: High reduction and backdrivability ACTUATion SYSTEM with minimal lateral\
\ encumbrance\n\nAbstract: \n\nBusiness Description: Typical robotic actuation\
\ units have a motor and its transmission system aligned with the axis of the\
\ joint they actuate, resulting in large lateral encumbrance of the whole system.\n\
\nThis solution aims at solving this problem and allows to locate the last transmission\
\ stage at an arbitrary distance from the axis of the screw.\n\nTech Features:\
\ This invention consists in a class of actuation systems which is specifically\
\ designed to minimize the lateral encumbrance of the exoskeletal system to maximize\
\ its practical usability. Its core components are a motor coupled to a leadscrew\
\ or ballscrew system and a further (arbitrary) transmission system to connect\
\ the nut of the screw based transmission to the output wheel.\n\nFurthermore,\
\ this solution allows to displace the location of the screw with respect to the\
\ final transmission stage, allowing the adaptation of the location of the different\
\ stages of the system without influencing the overall behavior.The designed anti-blockage\
\ system guarantees proper functioning of each mechanical component and high back-drivability\
\ of the overall system even for high overall gearing.\n\nApplications: Robotics.\n\
\nAdvantages: Minimal lateral encumbrance; High gearing; Highly Back-drivable;\
\ Torque estimation through current measurement; Capability of dislocating the\
\ screw from the point of application of force."
- "Fluid filtering device based on a rotating valve pressure exchanger. Title: Fluid\
\ filtering device based on a rotating valve pressure exchanger\n\nAbstract: \n\
\nBusiness Description: The invention consists of an high pressure reciprocating\
\ pumping system equipped with an energy recovery device, intended for reverse\
\ osmosis plants. The patented device, descending by previous ENEA's patents,\
\ permits to realize water treatment plants with low energy consumption.\n\nTech\
\ Features: During ENEA's research in absorption refrigeration machines, have\
\ been patented several reciprocating pumping systems based on oil gear pumps\
\ coupled with an original self-adjusting rotating valve. Such a coupling, instead\
\ of the usual piston-rod-crank kinematic, has permitted to realize low cost and\
\ high reliability high pressure reciprocating pumps, called \"VR pumps\". Basing\
\ on the original know-how developed for the technology, a new invention has been\
\ patented, which consists to link a high pressure primary pump, VR type or not,\
\ to a second VR pump acted by the pressure of the waste water coming from the\
\ desalination plant, instead by pressurized oil as usual. Such second VR pump\
\ acts on the desalination circuit like an innovative pressure exchanger.\n\n\
Applications: Reverse osmosis desalination plants; Microfiltration desalination\
\ plants.\n\nAdvantages: Low cost; Easy scale up; Suitable for small plants; Low\
\ specific energy consumption."
- "Mechanical towing for automatic vehicle convoys. Title: Mechanical towing for\
\ automatic vehicle convoys\n\nAbstract: \n\nBusiness Description: The patent\
\ allows a mechanical coupling between vehicles in order to guarantee the safety\
\ and operation of a convoy of even 10 vehicles capable of circulating as if it\
\ were a single vehicle. This technology therefore allows a single driver in the\
\ head vehicle to automatically control the convoy of vehicles connected, revolutionizing\
\ the local transport systems with transport services that would otherwise not\
\ be feasible.\n\nTech Features: The patented mobile mechanical connection couples\
\ two vehicles and transforms them into a convoy that moves like a single unit.\
\ By means of an automatic guidance system, the coupled vehicles are able to synchronize\
\ automatically with the movements of the head vehicle, ensuring compliance with\
\ the trajectory of the head vehicle. The mechanical connection also acts as a\
\ safeguard in case of malfunctions and motion \"harmonizer\". This system allows\
\ single vehicles to form convoys driven by the driver only on the leading vehicle:\
\ free-flow car-sharing vehicles can be relocated from areas where they would\
\ be stationed for a long time to areas where there is demand, forming a convoy\
\ also of 10 vehicles and moving them with one driver; buses can be extended for\
\ the central sections of the transport lines with the highest demand without\
\ increasing the drivers; transport systems can be created in which small buses\
\ gather people on call in the suburbs and form a single convoy that crosses the\
\ center with a single driver. The patented coupling mechanism allows passenger\
\ transport companies to re-organize their services by means of convoys of vehicles\
\ which combine the maintenance of the optimum passenger capacity and the social\
\ requirements imposed by pandemic of COVID-19 and the containment measures taken.\n\
\nApplications: Car-sharing services; Logistics and goods distribution companies;\
\ Public and private transport with variable capacity.\n\nAdvantages: Certified\
\ transport system; Responsible automation; Flexible and client-oriented transport\
\ system; Efficiency of transport and sharing systems; Management cost reduction,\
\ creating capillary and high capacity services."
pipeline_tag: sentence-similarity
library_name: sentence-transformers
metrics:
- cosine_accuracy@1
- cosine_accuracy@3
- cosine_accuracy@5
- cosine_accuracy@10
- cosine_precision@1
- cosine_precision@3
- cosine_precision@5
- cosine_precision@10
- cosine_recall@1
- cosine_recall@3
- cosine_recall@5
- cosine_recall@10
- cosine_ndcg@10
- cosine_mrr@10
- cosine_map@100
model-index:
- name: SentenceTransformer based on AI-Growth-Lab/PatentSBERTa
results:
- task:
type: information-retrieval
name: Information Retrieval
dataset:
name: mnrl val
type: mnrl-val
metrics:
- type: cosine_accuracy@1
value: 0.039440203562340966
name: Cosine Accuracy@1
- type: cosine_accuracy@3
value: 0.08778625954198473
name: Cosine Accuracy@3
- type: cosine_accuracy@5
value: 0.14122137404580154
name: Cosine Accuracy@5
- type: cosine_accuracy@10
value: 0.2035623409669211
name: Cosine Accuracy@10
- type: cosine_precision@1
value: 0.039440203562340966
name: Cosine Precision@1
- type: cosine_precision@3
value: 0.029262086513994912
name: Cosine Precision@3
- type: cosine_precision@5
value: 0.028244274809160308
name: Cosine Precision@5
- type: cosine_precision@10
value: 0.020356234096692113
name: Cosine Precision@10
- type: cosine_recall@1
value: 0.039440203562340966
name: Cosine Recall@1
- type: cosine_recall@3
value: 0.08778625954198473
name: Cosine Recall@3
- type: cosine_recall@5
value: 0.14122137404580154
name: Cosine Recall@5
- type: cosine_recall@10
value: 0.2035623409669211
name: Cosine Recall@10
- type: cosine_ndcg@10
value: 0.10853541428278174
name: Cosine Ndcg@10
- type: cosine_mrr@10
value: 0.07969071852659648
name: Cosine Mrr@10
- type: cosine_map@100
value: 0.08979593108601017
name: Cosine Map@100
---
# SentenceTransformer based on AI-Growth-Lab/PatentSBERTa
This is a [sentence-transformers](https://www.SBERT.net) model finetuned from [AI-Growth-Lab/PatentSBERTa](https://huggingface.co/AI-Growth-Lab/PatentSBERTa). It maps sentences & paragraphs to a 768-dimensional dense vector space and can be used for semantic textual similarity, semantic search, paraphrase mining, text classification, clustering, and more.
## Model Details
### Model Description
- **Model Type:** Sentence Transformer
- **Base model:** [AI-Growth-Lab/PatentSBERTa](https://huggingface.co/AI-Growth-Lab/PatentSBERTa) <!-- at revision 3ff1d553c861d8f5bfd902333d97fc95eb6b4c8f -->
- **Maximum Sequence Length:** 384 tokens
- **Output Dimensionality:** 768 dimensions
- **Similarity Function:** Cosine Similarity
<!-- - **Training Dataset:** Unknown -->
<!-- - **Language:** Unknown -->
<!-- - **License:** Unknown -->
### Model Sources
- **Documentation:** [Sentence Transformers Documentation](https://sbert.net)
- **Repository:** [Sentence Transformers on GitHub](https://github.com/huggingface/sentence-transformers)
- **Hugging Face:** [Sentence Transformers on Hugging Face](https://huggingface.co/models?library=sentence-transformers)
### Full Model Architecture
```
SentenceTransformer(
(0): Transformer({'max_seq_length': 384, 'do_lower_case': False, 'architecture': 'MPNetModel'})
(1): Pooling({'word_embedding_dimension': 768, 'pooling_mode_cls_token': True, 'pooling_mode_mean_tokens': False, 'pooling_mode_max_tokens': False, 'pooling_mode_mean_sqrt_len_tokens': False, 'pooling_mode_weightedmean_tokens': False, 'pooling_mode_lasttoken': False, 'include_prompt': True})
)
```
## Usage
### Direct Usage (Sentence Transformers)
First install the Sentence Transformers library:
```bash
pip install -U sentence-transformers
```
Then you can load this model and run inference.
```python
from sentence_transformers import SentenceTransformer
# Download from the 🤗 Hub
model = SentenceTransformer("sentence_transformers_model_id")
# Run inference
sentences = [
'High reduction and backdrivability ACTUATion SYSTEM with minimal lateral encumbrance. Title: High reduction and backdrivability ACTUATion SYSTEM with minimal lateral encumbrance\n\nAbstract: \n\nBusiness Description: Typical robotic actuation units have a motor and its transmission system aligned with the axis of the joint they actuate, resulting in large lateral encumbrance of the whole system.\n\nThis solution aims at solving this problem and allows to locate the last transmission stage at an arbitrary distance from the axis of the screw.\n\nTech Features: This invention consists in a class of actuation systems which is specifically designed to minimize the lateral encumbrance of the exoskeletal system to maximize its practical usability. Its core components are a motor coupled to a leadscrew or ballscrew system and a further (arbitrary) transmission system to connect the nut of the screw based transmission to the output wheel.\n\nFurthermore, this solution allows to displace the location of the screw with respect to the final transmission stage, allowing the adaptation of the location of the different stages of the system without influencing the overall behavior.The designed anti-blockage system guarantees proper functioning of each mechanical component and high back-drivability of the overall system even for high overall gearing.\n\nApplications: Robotics.\n\nAdvantages: Minimal lateral encumbrance; High gearing; Highly Back-drivable; Torque estimation through current measurement; Capability of dislocating the screw from the point of application of force.',
'High reduction and backdrivability ACTUATion SYSTEM with minimal lateral encumbrance. Title: High reduction and backdrivability ACTUATion SYSTEM with minimal lateral encumbrance\n\nAbstract: \n\nBusiness Description: Typical robotic actuation units have a motor and its transmission system aligned with the axis of the joint they actuate, resulting in large lateral encumbrance of the whole system.\n\nThis solution aims at solving this problem and allows to locate the last transmission stage at an arbitrary distance from the axis of the screw.\n\nTech Features: This invention consists in a class of actuation systems which is specifically designed to minimize the lateral encumbrance of the exoskeletal system to maximize its practical usability. Its core components are a motor coupled to a leadscrew or ballscrew system and a further (arbitrary) transmission system to connect the nut of the screw based transmission to the output wheel.\n\nFurthermore, this solution allows to displace the location of the screw with respect to the final transmission stage, allowing the adaptation of the location of the different stages of the system without influencing the overall behavior.The designed anti-blockage system guarantees proper functioning of each mechanical component and high back-drivability of the overall system even for high overall gearing.\n\nApplications: Robotics.\n\nAdvantages: Minimal lateral encumbrance; High gearing; Highly Back-drivable; Torque estimation through current measurement; Capability of dislocating the screw from the point of application of force.',
'Mechanical towing for automatic vehicle convoys. Title: Mechanical towing for automatic vehicle convoys\n\nAbstract: \n\nBusiness Description: The patent allows a mechanical coupling between vehicles in order to guarantee the safety and operation of a convoy of even 10 vehicles capable of circulating as if it were a single vehicle. This technology therefore allows a single driver in the head vehicle to automatically control the convoy of vehicles connected, revolutionizing the local transport systems with transport services that would otherwise not be feasible.\n\nTech Features: The patented mobile mechanical connection couples two vehicles and transforms them into a convoy that moves like a single unit. By means of an automatic guidance system, the coupled vehicles are able to synchronize automatically with the movements of the head vehicle, ensuring compliance with the trajectory of the head vehicle. The mechanical connection also acts as a safeguard in case of malfunctions and motion "harmonizer". This system allows single vehicles to form convoys driven by the driver only on the leading vehicle: free-flow car-sharing vehicles can be relocated from areas where they would be stationed for a long time to areas where there is demand, forming a convoy also of 10 vehicles and moving them with one driver; buses can be extended for the central sections of the transport lines with the highest demand without increasing the drivers; transport systems can be created in which small buses gather people on call in the suburbs and form a single convoy that crosses the center with a single driver. The patented coupling mechanism allows passenger transport companies to re-organize their services by means of convoys of vehicles which combine the maintenance of the optimum passenger capacity and the social requirements imposed by pandemic of COVID-19 and the containment measures taken.\n\nApplications: Car-sharing services; Logistics and goods distribution companies; Public and private transport with variable capacity.\n\nAdvantages: Certified transport system; Responsible automation; Flexible and client-oriented transport system; Efficiency of transport and sharing systems; Management cost reduction, creating capillary and high capacity services.',
]
embeddings = model.encode(sentences)
print(embeddings.shape)
# [3, 768]
# Get the similarity scores for the embeddings
similarities = model.similarity(embeddings, embeddings)
print(similarities)
# tensor([[1.0000, 1.0000, 0.5066],
# [1.0000, 1.0000, 0.5066],
# [0.5066, 0.5066, 1.0000]])
```
<!--
### Direct Usage (Transformers)
<details><summary>Click to see the direct usage in Transformers</summary>
</details>
-->
<!--
### Downstream Usage (Sentence Transformers)
You can finetune this model on your own dataset.
<details><summary>Click to expand</summary>
</details>
-->
<!--
### Out-of-Scope Use
*List how the model may foreseeably be misused and address what users ought not to do with the model.*
-->
## Evaluation
### Metrics
#### Information Retrieval
* Dataset: `mnrl-val`
* Evaluated with [<code>InformationRetrievalEvaluator</code>](https://sbert.net/docs/package_reference/sentence_transformer/evaluation.html#sentence_transformers.evaluation.InformationRetrievalEvaluator)
| Metric | Value |
|:--------------------|:-----------|
| cosine_accuracy@1 | 0.0394 |
| cosine_accuracy@3 | 0.0878 |
| cosine_accuracy@5 | 0.1412 |
| cosine_accuracy@10 | 0.2036 |
| cosine_precision@1 | 0.0394 |
| cosine_precision@3 | 0.0293 |
| cosine_precision@5 | 0.0282 |
| cosine_precision@10 | 0.0204 |
| cosine_recall@1 | 0.0394 |
| cosine_recall@3 | 0.0878 |
| cosine_recall@5 | 0.1412 |
| cosine_recall@10 | 0.2036 |
| **cosine_ndcg@10** | **0.1085** |
| cosine_mrr@10 | 0.0797 |
| cosine_map@100 | 0.0898 |
<!--
## Bias, Risks and Limitations
*What are the known or foreseeable issues stemming from this model? You could also flag here known failure cases or weaknesses of the model.*
-->
<!--
### Recommendations
*What are recommendations with respect to the foreseeable issues? For example, filtering explicit content.*
-->
## Training Details
### Training Dataset
#### Unnamed Dataset
* Size: 6,288 training samples
* Columns: <code>sentence_0</code> and <code>sentence_1</code>
* Approximate statistics based on the first 1000 samples:
| | sentence_0 | sentence_1 |
|:--------|:---------------------------------------------------------------------------------|:----------------------------------------------------------------------------------|
| type | string | string |
| details | <ul><li>min: 4 tokens</li><li>mean: 12.3 tokens</li><li>max: 35 tokens</li></ul> | <ul><li>min: 8 tokens</li><li>mean: 12.08 tokens</li><li>max: 36 tokens</li></ul> |
* Samples:
| sentence_0 | sentence_1 |
|:--------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------------------------------|
| <code>Epigenetic regulation system for the control of target gene expression</code> | <code>Applicant/Organization: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA</code> |
| <code>System integrating a membrane humidifier and an adsorption-based storage for polymer membrane hydrogen fuel cell applications.</code> | <code>Technical Classification: H01M</code> |
| <code>Superconducting bipolar thermoelectric memory</code> | <code>Technical Classification: G11C_11</code> |
* Loss: [<code>MultipleNegativesRankingLoss</code>](https://sbert.net/docs/package_reference/sentence_transformer/losses.html#multiplenegativesrankingloss) with these parameters:
```json
{
"scale": 20.0,
"similarity_fct": "cos_sim",
"gather_across_devices": false
}
```
### Training Hyperparameters
#### Non-Default Hyperparameters
- `eval_strategy`: steps
- `per_device_train_batch_size`: 12
- `per_device_eval_batch_size`: 12
- `num_train_epochs`: 10
- `multi_dataset_batch_sampler`: round_robin
#### All Hyperparameters
<details><summary>Click to expand</summary>
- `do_predict`: False
- `eval_strategy`: steps
- `prediction_loss_only`: True
- `per_device_train_batch_size`: 12
- `per_device_eval_batch_size`: 12
- `gradient_accumulation_steps`: 1
- `eval_accumulation_steps`: None
- `torch_empty_cache_steps`: None
- `learning_rate`: 5e-05
- `weight_decay`: 0.0
- `adam_beta1`: 0.9
- `adam_beta2`: 0.999
- `adam_epsilon`: 1e-08
- `max_grad_norm`: 1
- `num_train_epochs`: 10
- `max_steps`: -1
- `lr_scheduler_type`: linear
- `lr_scheduler_kwargs`: None
- `warmup_ratio`: None
- `warmup_steps`: 0
- `log_level`: passive
- `log_level_replica`: warning
- `log_on_each_node`: True
- `logging_nan_inf_filter`: True
- `enable_jit_checkpoint`: False
- `save_on_each_node`: False
- `save_only_model`: False
- `restore_callback_states_from_checkpoint`: False
- `use_cpu`: False
- `seed`: 42
- `data_seed`: None
- `bf16`: False
- `fp16`: False
- `bf16_full_eval`: False
- `fp16_full_eval`: False
- `tf32`: None
- `local_rank`: -1
- `ddp_backend`: None
- `debug`: []
- `dataloader_drop_last`: False
- `dataloader_num_workers`: 0
- `dataloader_prefetch_factor`: None
- `disable_tqdm`: False
- `remove_unused_columns`: True
- `label_names`: None
- `load_best_model_at_end`: False
- `ignore_data_skip`: False
- `fsdp`: []
- `fsdp_config`: {'min_num_params': 0, 'xla': False, 'xla_fsdp_v2': False, 'xla_fsdp_grad_ckpt': False}
- `accelerator_config`: {'split_batches': False, 'dispatch_batches': None, 'even_batches': True, 'use_seedable_sampler': True, 'non_blocking': False, 'gradient_accumulation_kwargs': None}
- `parallelism_config`: None
- `deepspeed`: None
- `label_smoothing_factor`: 0.0
- `optim`: adamw_torch_fused
- `optim_args`: None
- `group_by_length`: False
- `length_column_name`: length
- `project`: huggingface
- `trackio_space_id`: trackio
- `ddp_find_unused_parameters`: None
- `ddp_bucket_cap_mb`: None
- `ddp_broadcast_buffers`: False
- `dataloader_pin_memory`: True
- `dataloader_persistent_workers`: False
- `skip_memory_metrics`: True
- `push_to_hub`: False
- `resume_from_checkpoint`: None
- `hub_model_id`: None
- `hub_strategy`: every_save
- `hub_private_repo`: None
- `hub_always_push`: False
- `hub_revision`: None
- `gradient_checkpointing`: False
- `gradient_checkpointing_kwargs`: None
- `include_for_metrics`: []
- `eval_do_concat_batches`: True
- `auto_find_batch_size`: False
- `full_determinism`: False
- `ddp_timeout`: 1800
- `torch_compile`: False
- `torch_compile_backend`: None
- `torch_compile_mode`: None
- `include_num_input_tokens_seen`: no
- `neftune_noise_alpha`: None
- `optim_target_modules`: None
- `batch_eval_metrics`: False
- `eval_on_start`: False
- `use_liger_kernel`: False
- `liger_kernel_config`: None
- `eval_use_gather_object`: False
- `average_tokens_across_devices`: True
- `use_cache`: False
- `prompts`: None
- `batch_sampler`: batch_sampler
- `multi_dataset_batch_sampler`: round_robin
- `router_mapping`: {}
- `learning_rate_mapping`: {}
</details>
### Training Logs
| Epoch | Step | Training Loss | mnrl-val_cosine_ndcg@10 |
|:------:|:----:|:-------------:|:-----------------------:|
| 1.6835 | 500 | 0.0001 | - |
| 0.0954 | 50 | - | 0.0077 |
| 0.1908 | 100 | - | 0.0105 |
| 0.2863 | 150 | - | 0.0147 |
| 0.3817 | 200 | - | 0.0205 |
| 0.4771 | 250 | - | 0.0240 |
| 0.5725 | 300 | - | 0.0324 |
| 0.6679 | 350 | - | 0.0348 |
| 0.7634 | 400 | - | 0.0332 |
| 0.8588 | 450 | - | 0.0445 |
| 0.9542 | 500 | 2.3022 | 0.0491 |
| 1.0 | 524 | - | 0.0473 |
| 1.0496 | 550 | - | 0.0479 |
| 1.1450 | 600 | - | 0.0491 |
| 1.2405 | 650 | - | 0.0466 |
| 1.3359 | 700 | - | 0.0593 |
| 1.4313 | 750 | - | 0.0547 |
| 1.5267 | 800 | - | 0.0516 |
| 1.6221 | 850 | - | 0.0596 |
| 1.7176 | 900 | - | 0.0596 |
| 1.8130 | 950 | - | 0.0681 |
| 1.9084 | 1000 | 1.9086 | 0.0667 |
| 2.0 | 1048 | - | 0.0666 |
| 2.0038 | 1050 | - | 0.0686 |
| 2.0992 | 1100 | - | 0.0732 |
| 2.1947 | 1150 | - | 0.0686 |
| 2.2901 | 1200 | - | 0.0772 |
| 2.3855 | 1250 | - | 0.0752 |
| 2.4809 | 1300 | - | 0.0803 |
| 2.5763 | 1350 | - | 0.0721 |
| 2.6718 | 1400 | - | 0.0779 |
| 2.7672 | 1450 | - | 0.0745 |
| 2.8626 | 1500 | 1.6854 | 0.0866 |
| 2.9580 | 1550 | - | 0.0837 |
| 3.0 | 1572 | - | 0.0788 |
| 3.0534 | 1600 | - | 0.0752 |
| 3.1489 | 1650 | - | 0.0788 |
| 3.2443 | 1700 | - | 0.0845 |
| 3.3397 | 1750 | - | 0.0898 |
| 3.4351 | 1800 | - | 0.0920 |
| 3.5305 | 1850 | - | 0.0877 |
| 3.6260 | 1900 | - | 0.0926 |
| 3.7214 | 1950 | - | 0.0858 |
| 3.8168 | 2000 | 1.5140 | 0.0889 |
| 3.9122 | 2050 | - | 0.0882 |
| 4.0 | 2096 | - | 0.0848 |
| 4.0076 | 2100 | - | 0.0828 |
| 4.1031 | 2150 | - | 0.0910 |
| 4.1985 | 2200 | - | 0.0928 |
| 4.2939 | 2250 | - | 0.0913 |
| 4.3893 | 2300 | - | 0.0923 |
| 4.4847 | 2350 | - | 0.0888 |
| 4.5802 | 2400 | - | 0.0882 |
| 4.6756 | 2450 | - | 0.0987 |
| 4.7710 | 2500 | 1.3415 | 0.0954 |
| 4.8664 | 2550 | - | 0.0911 |
| 4.9618 | 2600 | - | 0.0932 |
| 5.0 | 2620 | - | 0.0887 |
| 5.0573 | 2650 | - | 0.0952 |
| 5.1527 | 2700 | - | 0.0954 |
| 5.2481 | 2750 | - | 0.0972 |
| 5.3435 | 2800 | - | 0.0957 |
| 5.4389 | 2850 | - | 0.0999 |
| 5.5344 | 2900 | - | 0.0964 |
| 5.6298 | 2950 | - | 0.0980 |
| 5.7252 | 3000 | 1.2411 | 0.0959 |
| 5.8206 | 3050 | - | 0.0943 |
| 5.9160 | 3100 | - | 0.0963 |
| 6.0 | 3144 | - | 0.0914 |
| 6.0115 | 3150 | - | 0.0915 |
| 6.1069 | 3200 | - | 0.0974 |
| 6.2023 | 3250 | - | 0.1019 |
| 6.2977 | 3300 | - | 0.1014 |
| 6.3931 | 3350 | - | 0.1037 |
| 6.4885 | 3400 | - | 0.0987 |
| 6.5840 | 3450 | - | 0.1010 |
| 6.6794 | 3500 | 1.1304 | 0.1064 |
| 6.7748 | 3550 | - | 0.1085 |
### Framework Versions
- Python: 3.12.12
- Sentence Transformers: 5.2.3
- Transformers: 5.0.0
- PyTorch: 2.10.0+cu128
- Accelerate: 1.13.0
- Datasets: 4.0.0
- Tokenizers: 0.22.2
## Citation
### BibTeX
#### Sentence Transformers
```bibtex
@inproceedings{reimers-2019-sentence-bert,
title = "Sentence-BERT: Sentence Embeddings using Siamese BERT-Networks",
author = "Reimers, Nils and Gurevych, Iryna",
booktitle = "Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing",
month = "11",
year = "2019",
publisher = "Association for Computational Linguistics",
url = "https://arxiv.org/abs/1908.10084",
}
```
#### MultipleNegativesRankingLoss
```bibtex
@misc{henderson2017efficient,
title={Efficient Natural Language Response Suggestion for Smart Reply},
author={Matthew Henderson and Rami Al-Rfou and Brian Strope and Yun-hsuan Sung and Laszlo Lukacs and Ruiqi Guo and Sanjiv Kumar and Balint Miklos and Ray Kurzweil},
year={2017},
eprint={1705.00652},
archivePrefix={arXiv},
primaryClass={cs.CL}
}
```
<!--
## Glossary
*Clearly define terms in order to be accessible across audiences.*
-->
<!--
## Model Card Authors
*Lists the people who create the model card, providing recognition and accountability for the detailed work that goes into its construction.*
-->
<!--
## Model Card Contact
*Provides a way for people who have updates to the Model Card, suggestions, or questions, to contact the Model Card authors.*
--> |